Our nephrologists use inj streptokinase to restore potency to thrombosed haemodialysis catheter
and they dilute one vial of 75000 iu in 100 ml normal saline or water for injection
then use 3 ml only and the remaining is discarded.
1- Are you doing same preparations and dilution?
2- If the dilution is ok what is the maximum stability after the reconstitution?
I appreciate your help
I’ve always also been through using Alteplase for the purpose of catheter occlusion in HD patients. However, it was an excellent opportunity to revise the use of streptokinase for such purpose.
Kindly find the below:-
1- Stability was found to be (8) hours in room temperature due to risk of contamination.
2- Stability was found to be (24) hours in refrigerator
3- I’d like to go with Naveed regarding the preferable use of Alteplase over Streptokinase because:-
Thanks for such refreshing inquiry.
– Generally speaking, initial treatment of intrinsic catheter-related thrombosis can be attempted within the hemodialysis facility and consists of first a forceful saline flush (risk of catheter rupture), and if not successful, intraluminal lytic enzyme instillation. If these 2 approaches didn’t work, then the catheter needs to be replaced.
– I think using 3 ml and wasting 97 ml (72750 IU) is not a cost-effective option, taking into consideration the high cost of Streptokinase that can be saved for other indications.
– Most of the available evidence recommended using catheter instillation with Alteplase 1-2 mg, which is available in appropriate strength to prevent unnecessary waste.
– In the past, urokinase was used as the agent of choice for this purpose and was reasonably effective. However, tissue plasminogen activator (tPA) has replaced urokinase for this purpose and has been shown to be significantly more effective 1,2,3.
– we are using intra-catheter Alteplase (Cathflo) 1-2 mg for catheter occlusion which seems safe, effective and cost-effective option.
1- Eyrich H, et al. Alteplase versus urokinase in restoring blood flow in hemodialysis-catheter thrombosis. J Health Syst Pharm. 2002;59(15):1437.
2- Haire WD, et al.Urokinase versus recombinant tissue plasminogen activator in thrombosed central venous catheters: a double-blinded, randomized trial. 1994;72(4):543.
3- Zacharias JM, et al. Alteplase versus urokinase for occluded hemodialysis catheters. Ann Pharmacother. 2003;37(1):27.
You must be logged in to reply to this topic.